Start with context
Questions are not a test of trust. They are part of informed decision-making.
Ibogaine is associated with potentially serious risks, and conversations about it can move quickly from hopeful claims to practical decisions. Before speaking with a provider or trial team, it can help to review the broader questions around whether ibogaine treatment works alongside the safety issues that may shape an individual situation.
This checklist is informational, not an endorsement of any provider, protocol, or treatment. It does not establish that a particular process is safe or appropriate. A provider’s answers should be specific, understandable, and open about limits as well as possible benefits.
“A clear answer can include uncertainty. A careful conversation should make room for it.”
01 / People & preparation
Ask who is responsible before, during, and after treatment.
Start with the people making clinical and safety decisions. Ask what licenses, training, and experience the responsible clinicians have; who reviews medical history; who is physically present during care; and how responsibilities are divided. This is especially important when claims about care involve facilities outside a person’s usual health system, including information encountered through an ibogaine clinic in Tijuana.
Who evaluates medical suitability?
Ask which clinician conducts the evaluation, what information they review, and whether the decision process is documented.
What is checked beforehand?
Ask whether the evaluation includes an ECG, a complete medications review, substance-use history, and other health information relevant to risk.
How are medication changes handled?
Ask who assesses possible interactions, who explains any changes, and how decisions are coordinated with a person’s existing medical care.
What is excluded—and why?
Ask how the team identifies circumstances in which participation may not be appropriate and how they communicate those limits.
02 / Safety planning
Ask for a concrete account of how emergencies are recognized and managed.
It is reasonable to ask what monitoring occurs, what equipment and medicines are available, who can respond to an emergency, and what transfer arrangements exist if a higher level of care is needed. The FDA’s drug-safety communications illustrate why clear discussion of serious adverse effects and response plans matters when medicines may carry significant risk.
- What monitoring is used before, during, and after administration?
- What emergency protocols are in place, and who leads them?
- How would a transfer to emergency or hospital care be arranged?
- How are adverse events recorded, reviewed, and communicated?
03 / Evidence & outcomes
Ask what outcomes are measured—not only what stories are shared.
Ask what the provider or trial team means by success, how outcomes are measured, how long people are followed, and what happens to people who do not improve or who leave early. Questions about addiction outcomes should include follow-up care, relapse, retention, and adverse events—not only short-term changes. The National Institute on Drug Abuse overview of treatment research notes that treatment is not one event and can involve different evidence-based approaches over time.
Be alert to broad claims that stretch beyond the available evidence. Similar care is sometimes discussed for different conditions, including through pages about ibogaine and Parkinson’s disease, but a condition-specific claim still needs condition-specific evidence and careful clinical context.
Questions to use when outcomes are discussed
Ask: “What outcomes do you track?” “At what intervals?” “How are adverse events defined and reported?” “Can you describe limits in your data?” and “What follow-up support is offered for substance use after the immediate treatment period?”
Questions to use when a clinical trial is mentioned
Ask for the trial’s registration, eligibility criteria, oversight, consent process, study endpoints, and who to contact independently with participant-rights questions. Clinical research is different from routine treatment, and participation may not provide personal benefit.
04 / Consent & legal status
Ask what informed consent explains—and what it does not promise.
Informed consent should be more than a signature. Ask whether it describes foreseeable risks, uncertainty, alternatives, the possibility of no benefit, what information is collected, and what choices remain available if someone changes their mind. The general meaning of informed consent includes a person’s voluntary agreement after receiving relevant information, not an assurance that an outcome will occur.
Legal and regulatory status can differ by location and can change. Ask where the service operates, what rules apply there, whether the activity is presented as treatment or research, and how the provider explains those distinctions. This is a practical question even when reading broader material about ibogaine plant seeds, because the status of a plant, compound, product, or service may not be interchangeable.
For a clearer sense of this resource’s careful, non-promotional approach, the principles behind Cautera’s information describe why uncertainty and safety clarity should remain visible in these conversations.
05 / Follow-up care
Ask what support exists after the immediate experience ends.
For people affected by substance use, follow-up may be as important to ask about as the immediate intervention. Ask what recovery support, mental health care, medical follow-up, crisis planning, and coordination with local services are available. A page focused on ibogaine treatment for drug addiction can raise relevant topics, but it should not substitute for asking how ongoing care will be planned for an individual.
Bring these questions to a qualified healthcare professional who knows the person’s history when possible. It can also be useful to write down answers, note what remains unclear, and compare claims against the evidence-focused material at Does Ibogaine Treatment Work. No provider should require a decision before a person has had time to understand the information and discuss it with people they trust.
A short closing checklist
Before making a decision, ask whether you understand who is responsible for care, how medical risks are evaluated, what happens in an emergency, what outcomes and adverse events are tracked, what consent means, what rules apply, and what support follows afterward.